Post-Bariatric Hypoglycemia Market

Market Overview:

The 7 major post-bariatric hypoglycemia markets are expected to exhibit a CAGR of 5.28% during 2024-2034.

The post-bariatric hypoglycemia market has been comprehensively analyzed in IMARC's new report titled "Post-Bariatric Hypoglycemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post-bariatric hypoglycemia refers to a metabolic condition that can develop after weight loss surgery, such as gastric bypass or sleeve gastrectomy. It is characterized by recurrent episodes of low blood sugar levels, typically occurring 1 to 3 hours after meals. These episodes of hypoglycemia can lead to a range of symptoms, including dizziness, confusion, irritability, sweating, shakiness, and, in severe cases, loss of consciousness. The diagnosis of this ailment can be challenging as signs can be non-specific and overlap with several other post-operative complications or conditions. However, the healthcare professional might perform a comprehensive evaluation of the patient's medical history, indications, and blood sugar levels. Glucose monitoring during fasting and after meals is also recommended to identify the presence of low blood sugar episodes. Additionally, various tests to measure insulin levels and numerous other hormonal factors may be conducted to better recognize the underlying mechanisms contributing to the condition.

The escalating incidences of post-operative complications following bariatric surgery, particularly concerning the rapid insulin release resulting in low blood sugar, are primarily driving the post-bariatric hypoglycemia market. In addition to this, the inflating utilization of effective medications, such as glucagon-like peptide-1 (GLP-1) agonists, diazoxide, and somatostatin analogs for managing the condition and mitigating its impact is creating a positive outlook for the market. Moreover, the widespread adoption of nutritional counseling and personalized meal plans, which aid in stabilizing blood sugar fluctuations and promoting optimal glucose management, is further bolstering the market growth. Apart from this, the rising usage of novel therapeutic approaches like pancreatic islet transplantation, since it involves implanting insulin-producing cells to restore glucose equilibrium and enhance the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of continuous glucose monitoring systems that have revolutionized patient care by allowing real-time tracking of blood sugar levels and enabling timely interventions to avert hypoglycemic episodes, is also augmenting the market growth. Furthermore, the increasing application of advanced medical technologies, such as closed-loop insulin delivery systems, which improve treatment adherence and reduce the likelihood of neglecting glucose management tasks, is expected to drive the post-bariatric hypoglycemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the post-bariatric hypoglycemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for post-bariatric hypoglycemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post-bariatric hypoglycemia market in any manner.

Recent Developments:

• In October 2023, MBX Biosciences, Inc. revealed that it had dosed the first healthy adult participant in its Phase 1/2 clinical study of MBX 1416, a long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist being developed for the management of post-bariatric hypoglycemia.
• In August 2023, Vogenx initiated a Phase 2 clinical investigation of mizagliflozin for the treatment of post-bariatric hypoglycemia. The study aims to determine the dose strengths and frequency of administration to be used in future clinical studies.

Key Highlights:

• Post-bariatric hypoglycemia is considered a rare incidence (approximately 0.1% to 1%), primarily because it was examined through emergency room access records.
• The frequency of post-bariatric hypoglycemia varies according to the diagnostic techniques utilized. Recent studies have found a prevalence of up to 88% using a mixed meal tolerance test (MMTT)1 and 75% using continuous glucose monitoring (CGM).
• Notably, fewer than 30% of persons with the illness report any symptoms in an everyday context.
• Some people have hypoglycemia more than a year following bariatric surgery.

Drugs:

Pasireotide is under clinical development by Recordati for the treatment of post-bariatric hypoglycemia. Pasireotide is a synthetic polypeptide homolog of somatostatin. It comes in the form of an injectable solution and a powder for suspension intended for subcutaneous administration.

Mizagliflozin is a new first-in-class small molecule treatment candidate being investigated for post-bariatric hypoglycemia. Mizagliflozin has been provided to approximately 500 participants in 9 clinical investigations and has demonstrated statistically significant decreases in postprandial glucose absorption and insulin secretion.

Avexitide is an experimental, first-in-class glucagon-like peptide-1 receptor (GLP-1r) antagonist being developed for the treatment of post-bariatric hypoglycemia. Avexitide reduces dysregulated insulin production and the occurrence of hypoglycemia by binding to the GLP-1r on pancreatic beta cells and inhibiting GLP-1r signaling.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the post-bariatric hypoglycemia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the post-bariatric hypoglycemia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current post-bariatric hypoglycemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the post-bariatric hypoglycemia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the post-bariatric hypoglycemia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the post-bariatric hypoglycemia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of post-bariatric hypoglycemia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with post-bariatric hypoglycemia across the seven major markets?
• What is the size of the post-bariatric hypoglycemia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of post-bariatric hypoglycemia?
• What will be the growth rate of patients across the seven major markets?
   

Post-Bariatric Hypoglycemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for post-bariatric hypoglycemia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post-bariatric hypoglycemia market?
• What are the key regulatory events related to the post-bariatric hypoglycemia market?
• What is the structure of clinical trial landscape by status related to the post-bariatric hypoglycemia market?
• What is the structure of clinical trial landscape by phase related to the post-bariatric hypoglycemia market?
• What is the structure of clinical trial landscape by route of administration related to the post-bariatric hypoglycemia market?